» Articles » PMID: 35922754

Toxic Leukoencephalopathy with Axonal Spheroids Caused by Chemotherapeutic Drugs Other Than Methotrexate

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2022 Aug 3
PMID 35922754
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The objective of this report is to share the clinicopathological features of chemotherapy-induced toxic leukoencephalopathy, which is a rare and under-recognized disease, clinically characterized by rapidly progressive cognitive loss that often leads to sudden death.

Case Presentation: A 64-year-old woman and a 63-year-old man, who had both suffered from a rapid deterioration of consciousness, were autopsied under the clinical impressions of either the central nervous system graft versus host disease (CNS-GVHD), infectious encephalitis, or autoimmune encephalitis. Both patients had been treated with multiple chemotherapy regimens, including adriamycin, cytarabine arabinoside, daunorubicin, fludarabine, azacitidine, and allogeneic peripheral blood stem cell transplantation to treat hematological malignancies (acute myelogenous leukemia and myelodysplastic syndrome). Neuropathological findings at autopsy revealed rarefaction and vacuolar changes of the white matter with axonal spheroids, reactive gliosis, and foamy macrophage infiltration, predominantly in the visual pathways of the occipital and temporal lobes. Damaged axons exhibited immunoreactivity to beta-amyloid, consistent with axonopathy. However, there was no lymphocyte infiltration that suggested CNS-GVHD or any type of encephalitis.

Conclusion: The neuropathology found in the presented cases had the characteristic features of toxic leukoencephalopathy (chemobrain). Our cases showed that toxic leukoencephalopathy can also be caused by chemotherapy drugs other than methotrexate.

Citing Articles

Acute Graft--Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System.

Vinnakota J, Zeiser R Front Immunol. 2021; 12:748019.

PMID: 34691059 PMC: 8527894. DOI: 10.3389/fimmu.2021.748019.

References
1.
Pearre D, Bota D . Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients. Expert Rev Qual Life Cancer Care. 2019; 3(1):19-26. PMC: 6377208. DOI: 10.1080/23809000.2018.1443811. View

2.
Zabernigg A, Maier H, Thaler J, Gattringer C . Late-onset fatal neurological toxicity of fludarabine. Lancet. 1994; 344(8939-8940):1780. DOI: 10.1016/s0140-6736(94)92922-x. View

3.
Matsubayashi J, Tsuchiya K, Matsunaga T, Mukai K . Methotrexate-related leukoencephalopathy without radiation therapy: distribution of brain lesions and pathological heterogeneity on two autopsy cases. Neuropathology. 2008; 29(2):105-15. DOI: 10.1111/j.1440-1789.2008.00945.x. View

4.
Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T . TMEM119 marks a subset of microglia in the human brain. Neuropathology. 2015; 36(1):39-49. DOI: 10.1111/neup.12235. View

5.
Cifci Sunamak E, Ozdemir N, Celkan T . Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols. Pediatr Blood Cancer. 2019; 66(6):e27711. DOI: 10.1002/pbc.27711. View